Slide 1: Q3/9M 2022 Results
Q3/9M 2022 Results Matthias Gaertner, CEO Falk Neukirch, CFO November 10, 2022
Slide 2: Agenda
1 Executive summary 2 Financial overview 3 Guidance 2022, growth story, ESG 4 Appendix 2
Slide 3: Highlights 9M 2022: Strong financials with KPIs at record levels
Executive summary Highlights 9M 2022: Strong financials with KPIs at record levels • Milestone reached in PST segment1: Manufacturing permit granted for new GMP2-lab in Berlin – increasing compounding capacities and optimized logistics • NewCo Pharma integration progressing well: Ongoing synergy and
Slide 4: Growth and earnings achieve record levels
Key financials Growth and earnings achieve record levels Revenue €m EBITDA pre¹ €m 393 399 419 369 15.3 354 14.3 319 14.1 316 10.2 9.5 10.0 8.8 174 163 160 130 4.8 4.3 3.8 2.7 margin 2.2 3.7 2.6 3.0 2.8 2.8 3.6 3.6 2.8 2.4 2.8 1.7 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 202
Slide 5: 9M 2022 – Continuous and sustainable growth
Executive summary 9M 2022 – Continuous and sustainable growth Revenue EBITDA pre¹ in €m in €m + 22.5% + 55.1% 43.8 1,211 989 28.2 9M 2021 9M 2022 9M 2021 9M 2022 ¹ EBITDA without extraordinary expenses: adjusted for extraordinary expenses for stock options & M&A activities 5
Slide 6: 9M 2022 – Split by operative segments
Executive summary 9M 2022 – Split by operative segments: Significant rise of PST significantly increased Revenue by segment EBITDA pre by segment 14% 41% 86% 59% Pharmaceutical Supply Pharmaceutical Supply Patient-specific Therapies Patient-specific Therapies 6
Slide 7: Excellent geographic coverage through strong nationwide network of partners and own compounding facilities
Market positioning & business model Excellent geographic coverage through strong nationwide network of partners and own compounding facilities • 7 GMP1 / blistering labs Hamburg • 2 warehouses Berlin (HQ) Osnabruck • Around 600 specialized partner Berlin pharmacies Cologne • Around 320,000 individua
Slide 8: Agenda
1 Executive summary 2 Financial overview 3 Guidance 2022, growth story, ESG 4 Appendix 8
Slide 9: 9M 2022 – Financials
Financial overview 9M 2022 – Financials In € million 9M 2022 9M 2021 ∆% Revenue 1,211.4 988.8 22.5% • Revenue growth driven by NewCo integration: inorganic (+16%) & organic (+7%) Gross profit1 81.5 49.8 63.7% gross margin in % 6.7% 5.0% 34.0% • Disproportionate increase of gross and EBITDA pre margi
Slide 10: 9M 2022 – Ongoing organic and inorganic revenue growth
Financial overview 9M 2022 – Ongoing organic and inorganic revenue growth 9M YoY revenue in €m 9M 2021 Organic Inorganic 9M 2022 Pharmaceutical Supply (PS) 941.7 62.0 40.7 1,044.4 • Inorganic Growth (+15.8%; €+155.9m) Patient-specific Therapies (PST) 46.5 4.9 115.2 166.6 driven by NewCo acquisition
Slide 11: 9M 2022 – EBITDA pre driven by acquisition of NewCo Pharma
Financial overview 9M 2022 – EBITDA pre1 driven by acquisition of NewCo Pharma Inorganic 9M YoY EBITDA pre1 in €m 9M 2021 Organic 9M 2022 (NewCo only) Pharmaceutical Supply 23.8 1.2 3.1 28.2 • EBITDA pre of PS and PST segments grew mainly inorganically Patient-specific Therapies 6.0 0.7 12.7 19.3 •
Slide 12: 9M 2022 – Strong Group margin, mainly as a result of increased PST share
Financial overview 9M 2022 – Strong Group margin, mainly as a result of increased PST share Pharmaceutical Patient-specific Internal Services and Group Supply ‘PS‘ Therapies ‘PST’ IFRS consolidation In € million 9M 2022 9M 2021 9M 2022 9M 2021 9M 2022 9M 2021 9M 2022 9M 2021 Total segment revenue 1,
Slide 13: Agenda
1 Executive summary 2 Financial overview 3 Guidance 2022, growth story, ESG 4 Appendix 13
Slide 14: Guidance FY 2022 confirmed (1/2)
Guidance 2022 Guidance FY 2022 confirmed (1/2) Revenue EBITDA pre2 Comments in €m in €m Forecast confirmed despite ongoing + 6.8 - 17.9% + 35.3 - 50.9% global uncertainties Revenue expected to reach upper end of the range of €1.45-1.6bn 1,450 52 - 58 EBITDA pre1 expected to reach the lower – half of
Slide 15: Guidance FY 2022 confirmed (2/2) – Main assumptions
Guidance 2022 Guidance FY 2022 confirmed (2/2) – Main assumptions + The acquisition of NewCo Pharma will significantly contribute to external growth + Synergy effects as a result of the integration of Cranach Pharma & Newco Pharma: • Especially in purchasing and logistics • Cross-selling within exte
Slide 16: Medios' growth strategy
Growth strategy & ESG Medios’ growth strategy • Compounding capacities to triple as a result of • Compounding from partner pharmacies to be new labs in Berlin potentially integrated into Medios’ labs • Advance market penetration through innovative • Add further labs in case of geographical fit and/
Slide 17: Implementation of ambitious ESG strategy 2025 on track
Growth strategy & ESG Implementation of ambitious ESG strategy 2025 on track Rating Updates from MSCI and ISS ESG 2023 and beyond • Achieve climate neutrality at own sites in FY 2023 Focus on examination of energy-saving measures • Supplier Code of Conduct and assessment of throughout Medios Group s
Slide 18: Agenda
1 Executive summary 2 Financial overview 3 Guidance 2022, growth story, ESG 4 Appendix 18
Slide 19: Q3 / 9M 2022 - Key figures (1/2)
Appendix Q3 / 9M 2022 - Key figures (1/2) in € thousand 9M 2022 9M 2021 ∆ in % Q3 2022 Q3 2021 ∆ in % Revenue 1,211,397 988,765 22.5% 419,218 353,839 18.5% Pharmaceutical Supply 1,044,383 941,745 10.9% 361,926 338,185 7.0% Patient-Specific Therapies 166,626 46,544 258.0% 57,141 15,498 268.7% Service
Slide 20: Q3 / 9M 2022 - Key figures (2/2)
Appendix Q3 / 9M 2022 - Key figures (2/2) in € thousand 9M 2022 9M 2021 ∆ in % Q3 2022 Q3 2021 ∆ in % Earnings per share (in €) Undiluted 0.67 0.50 34.0% 0.25 0.18 38.9% Diluted 0.66 0.48 37.5% 0.25 0.17 47.1% Investments (CAPEX) 3.576 8,984 -60.0% 712 3,188 -77.7% Cash flow from operating activitie
Slide 21: Q3 2022 – Record quarter driven by NewCo acquisition and supported by organic growth
Financial overview Q3 2022 – Record quarter driven by NewCo acquisition and supported by organic growth Q3 YoY Revenue in €m Q3 2021 Organic Inorganic Q3 2022 Pharmaceutical Supply 338.2 10.1 13.6 361.9 • Inorganic growth driven by NewCo integration Patient-specific Therapies 15.5 1.7 40.1 57.1 • Or
Slide 22: Q3 2022 – Record quarter driven by NewCo acquisition
Financial overview Q3 2022 – Record quarter driven by NewCo acquisition Q3 YoY EBITDA pre* in €m Q3 2021 Organic Inorganic Q3 2022 Pharmaceutical Supply 8.6 1.1 1.1 10.7 • Successful integration of NewCo Patient-specific Therapies 2.0 0.3 3.7 6.1 Pharma led to EBITDA pre* contribution of €4.8m (€1.1
Slide 23: Q3 2022 – Strong Group margin, mainly as a result of increased PST share
Financial overview Q3 2022 – Strong Group margin, mainly as a result of increased PST share Pharmaceutical Patient-specific Internal Services and Group Supply ‘PS‘ Therapies ‘PST’ IFRS consolidation In € million Q3 2022 Q3 2021 Q3 2022 Q3 2021 Q3 2022 Q3 2021 Q3 2022 Q3 2021 Total segment revenue 38
Slide 24: Contact
Contact Claudia Nickolaus Head of Investor & Public Relations, ESG Communications Phone +49 30 232 566 800 c.nickolaus@medios.ag 24
Slide 25: Disclaimer
Disclaimer This presentation has been produced by Medios AG (the „Company“). The facts and information The forward-looking statements, including but not limited to assumptions, opinions and views of contained herein are as up to date as is reasonably possible and are subject to revision in the the C
Slide 26: Q3/9M 2022 Results
Q3/9M 2022 Results Matthias Gaertner, CEO Falk Neukirch, CFO November 10, 2022